Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 4/2024

Open Access 29-01-2024 | Positron Emission Tomography | Original Article

A first-in-man study of [18F] FEDAC: a novel PET tracer for the 18-kDa translocator protein

Authors: Kentaro Tamura, Ryuichi Nishii, Kotaro Tani, Hiroki Hashimoto, Kazunori Kawamura, Ming-Rong Zhang, Takamasa Maeda, Kana Yamazaki, Tatsuya Higashi, Masahiro Jinzaki

Published in: Annals of Nuclear Medicine | Issue 4/2024

Login to get access

Abstract

Purpose

N-benzyl-N-methyl-2-[7, 8-dihydro-7-(2-[18F] fluoroethyl) -8-oxo-2-phenyl-9H-purin-9-yl] acetamide ([18F] FEDAC) is a novel positron emission tomography (PET) tracer that targets the translocator protein (TSPO; 18 kDa) in the mitochondrial outer membrane, which is known to be upregulated in various diseases such as malignant tumors, neurodegenerative diseases, and neuroinflammation. This study presents the first attempt to use [18F]FEDAC PET/CT and evaluate its biodistribution as well as the systemic radiation exposure to the radiotracer in humans.

Materials and Methods

Seventeen whole-body [18F]FEDAC PET/CT (injected dose, 209.1 ± 6.2 MBq) scans with a dynamic scan of the upper abdomen were performed in seven participants. Volumes of interest were assigned to each organ, and a time–activity curve was created to evaluate the biodistribution of the radiotracer. The effective dose was calculated using IDAC-Dose 2.1.

Results

Immediately after the intravenous injection, the radiotracer accumulated significantly in the liver and was subsequently excreted into the gastrointestinal tract through the biliary tract. It also showed high levels of accumulation in the kidneys, but showed minimal migration to the urinary bladder. Thus, the liver was the principal organ that eliminated [18F] FEDAC. Accumulation in the normal brain tissue was minimal. The effective dose estimated from biodistribution in humans was 19.47 ± 1.08 µSv/MBq, and was 3.60 mSV for 185 MBq dose.

Conclusion

[18F]FEDAC PET/CT provided adequate image quality at an acceptable effective dose with no adverse effects. Therefore, [18F]FEDAC may be useful in human TSPO-PET imaging.
Literature
1.
Braestrup C, Albrechtsen R, Squires RF. High densities of benzodiazepine receptors in human cortical areas. Nature. 1977;269:702–4.ADSCrossRefPubMed
2.
Lacapère JJ, Papadopoulos V. Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis. Steroids. 2003;68:569–85.CrossRefPubMed
3.
Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapère J-J, Lindemann P, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27:402–9.CrossRefPubMed
4.
Camsonne R, Crouzel C, Comar D, Mazière M, Prenant C, Sastre J, et al. Synthesis of N-(11C) methyl, N-(methyl-1 propyl), (chloro-2 phenyl)-1 isoquinoleine carboxamide-3 (PK 11195): A new ligand for peripheral benzodiazepine receptors. J Labelled Comp Radiopharm. 1984;21:985–91.CrossRef
5.
Bhoola NH, Mbita Z, Hull R, Dlamini Z. Translocator Protein (TSPO) as a potential biomarker in human cancers. Int J Mol Sci. 2018.
6.
Batarseh A, Papadopoulos V. Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states. Mol Cell Endocrinol. 2010;327:1–12.CrossRefPubMedPubMedCentral
7.
Shah F, Hume SP, Pike VW, Ashworth S, McDermott J. Synthesis of the enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl Med Biol. 1994;21:573–81.CrossRefPubMed
8.
Petit-Taboué MC, Baron JC, Barré L, Travère JM, Speckel D, Camsonne R, et al. Brain kinetics and specific binding of [11C]PK 11195 to omega 3 sites in baboons: positron emission tomography study. Eur J Pharmacol. 1991;200:347–51.CrossRefPubMed
9.
Chauveau F, Boutin H, Van Camp N, Dollé F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35:2304–19.CrossRefPubMed
10.
Yanamoto K, Kumata K, Yamasaki T, Odawara C, Kawamura K, Yui J, et al. [18F]FEAC and [18F]FEDAC: Two novel positron emission tomography ligands for peripheral-type benzodiazepine receptor in the brain. Bioorg Med Chem Lett. 2009;19:1707–10.CrossRefPubMed
11.
Yanamoto K, Kumata K, Fujinaga M, Nengaki N, Takei M, Wakizaka H, et al. In vivo imaging and quantitative analysis of TSPO in rat peripheral tissues using small-animal PET with [18F]FEDAC. Nucl Med Biol. 2010;37:853–60.CrossRefPubMed
12.
Yui J, Maeda J, Kumata K, Kawamura K, Yanamoto K, Hatori A, et al. 18F-FEAC and 18F-FEDAC: PET of the monkey brain and imaging of translocator protein (18 kDa) in the infarcted rat brain. J Nucl Med. 2010;51:1301–9.CrossRefPubMed
13.
Xie L, Yui J, Hatori A, Yamasaki T, Kumata K, Wakizaka H, et al. Translocator protein (18 kDa), a potential molecular imaging biomarker for non-invasively distinguishing non-alcoholic fatty liver disease. J Hepatol. 2012;57:1076–82.CrossRefPubMed
14.
Maekawa K, Tsuji AB, Yamashita A, Sugyo A, Katoh C, Tang M, et al. Translocator protein imaging with 18F-FEDAC-positron emission tomography in rabbit atherosclerosis and its presence in human coronary vulnerable plaques. Atherosclerosis. 2021;337:7–17.CrossRefPubMed
15.
Luo R, Wang L, Ye F, Wang Y-R, Fang W, Zhang M-R, et al. [18F]FEDAC translocator protein positron emission tomography-computed tomography for early detection of mitochondrial dysfunction secondary to myocardial ischemia. Ann Nucl Med. 2021;35:927–36.CrossRefPubMedPubMedCentral
16.
Chung SJ, Yoon HJ, Youn H, Kim MJ, Lee Y-S, Jeong JM, et al. 18F-FEDAC as a targeting agent for activated macrophages in DBA/1 mice with collagen-induced arthritis: comparison with 18F-FDG. J Nucl Med. 2018;59:839–45.CrossRefPubMed
17.
Kawamura K, Kumata K, Takei M, Furutsuka K, Hashimoto H, Ito T, et al. Efficient radiosynthesis and non-clinical safety tests of the TSPO radioprobe [(18)F]FEDAC: Prerequisites for clinical application. Nucl Med Biol. 2016;43:445–53.CrossRefPubMed
18.
Ferrer L, Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Le Gouill S, Wegener WA, et al. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer. 2010;116:1093–100.CrossRefPubMed
19.
ICRP. Basic Anatomical and Physiological Data for Use in Radiological Protection Reference Values. ICRP Publication 89. Ann ICRP 2002;32:(3-4).
20.
Andersson M, Johansson L, Eckerman K, Mattsson S. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017.
21.
ICRP. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Ann ICRP 2007;37:(2-4).
22.
Hirvonen J, Roivainen A, Virta J, Helin S, Någren K, Rinne JO. Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation. Eur J Nucl Med Mol Imaging. 2010;37:606–12.CrossRefPubMed
23.
Fujimura Y, Kimura Y, Siméon FG, Dickstein LP, Pike VW, Innis RB, et al. Biodistribution and radiation dosimetry in humans of a New PET Ligand, 18F-PBR06, to image translocator protein (18 kDa). J Nucl Med. 2010;51:145–9.CrossRefPubMed
24.
Brody AL, Okita K, Shieh J, Liang L, Hubert R, Mamoun M, et al. Radiation dosimetry and biodistribution of the translocator protein radiotracer [11C]DAA1106 determined with PET/CT in healthy human volunteers. Nucl Med Biol. 2014;41:871–5.CrossRefPubMedPubMedCentral
25.
Takano A, Gulyás B, Varrone A, Karlsson P, Sjoholm N, Larsson S, et al. Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [18F]FEDAA1106: a human whole-body PET study. Eur J Nucl Med Mol Imaging. 2011;38:2058–65.CrossRefPubMed
26.
Mizrahi R, Rusjan PM, Vitcu I, Ng A, Wilson AA, Houle S, et al. Whole body biodistribution and radiation dosimetry in humans of a new PET ligand, [(18)F]-FEPPA, to image translocator protein (18 kDa). Mol Imaging Biol. 2013;15:353–9.CrossRefPubMed
Metadata
Title
A first-in-man study of [18F] FEDAC: a novel PET tracer for the 18-kDa translocator protein
Authors
Kentaro Tamura
Ryuichi Nishii
Kotaro Tani
Hiroki Hashimoto
Kazunori Kawamura
Ming-Rong Zhang
Takamasa Maeda
Kana Yamazaki
Tatsuya Higashi
Masahiro Jinzaki
Publication date
29-01-2024
Publisher
Springer Nature Singapore
Published in
Annals of Nuclear Medicine / Issue 4/2024
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-023-01895-0

Other articles of this Issue 4/2024

Annals of Nuclear Medicine 4/2024 Go to the issue

Original Article

Development and application of a fully automatic multi-function cassette module Mortenon M1 for radiopharmaceutical synthesis

Original Article

Methyl-11C-L-methionine positron emission tomography for radiotherapy planning for recurrent malignant glioma

Original Article

Simultaneous evaluation of brain metastasis and thoracic cancer using semiconductor 11C-methionine PET/CT imaging

Correction

Correction: Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects

Original Article

Left ventricular mechanical dyssynchrony after chemotherapy in breast cancer patients with normal rest gated SPECT-MPI

Original Article

Performance of 99mTc-PYP scintigraphy in the diagnosis of hereditary transthyretin cardiac amyloidosis